All In MedTech

Device Trial Radar · NCT03557892

Sensor-augmented Pump Versus Multiple Daily Injections With Degludec as Basal Insulin for Insulin Therapy in Type 1 Diabetes

Continuous Subcutaneous Insulin Infusion Associated With Continuous Glucose Monitoring in Comparison With Subcutaneous Multi-injection Insulin Therapy Using Degludec as Basal Insulin: a Randomized Crossover Trial in Type 1 Diabetes

Last checked: Nov 20, 2026Latest source record: Jul 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

28

Actual

Start

Apr 1, 2018

Primary completion

Dec 20, 2019

Study completion Jan 2, 2020

Sponsor

Lead sponsor
Azienda Ospedaliero-Universitaria CareggiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 15, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Several studies have shown that Continuous Subcutaneous Insulin Infusion together with Continuous Glucose Monitoring improves glycemic control in type 1 diabetes when compared to more traditional approaches; however, in available trials the basal insulin used in multi-injection therapy is typically glargine, which is associated with a higher hypoglycemic risk than degludec. This study will assess the efficacy and safety of Continuous Subcutaneous Insulin infusion (CSII) combined with Continuous Glucose Monitoring (CGM), as compared to Multiple Daily Injections (MDI) of insulin analogues, using degludec as basal insulin, associated with traditional self-monitoring of capillary blood glucose (SMBG) in patients with type 1 diabetes. A crossover design was chosen in order to minimize study sample improving statistical power.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • CGM+CSIIDevice

    Animas Vibe Platinum insulin pump and Dexcom G4 CGM

  • MDI with degludecDevice

    Multiple injection therapy with any short-acting analogue as bolus insulin and degludec as basal insulin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1cTime frame: 4 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Diabetologia AOU Careggi

    Florence, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.